UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff Deadline - Furuqi & Furuqi LLPUltragenyx Pharmaceuticals Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, March 03, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARENEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (
NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, March 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (
NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 DeadlinePHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (
NASDAQ: RARE) (“Ultragenyx” or the “Company”) on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025 (the “Class Period”).
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARENEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s shares between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineNEW YORK and NEW ORLEANS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARENEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (
NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (
NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Ultragenyx to Participate at Investor Conferences in MarchNOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (
NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
